<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114225</article-id><article-id pub-id-type="publisher-id">ACM-41616</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_34774150.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  液相色谱串联质谱法分析人体内儿茶酚胺及其代谢产物的研究进展
  Research Progress in the Analysis of Catecholamines and Their Metabolites in Human Body by Liquid Chromatography Tandem Mass Spectrometry
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>闫</surname><given-names>亚娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>猛</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>伦</surname><given-names>立民</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院检验科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1571</fpage><lpage>1578</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    儿茶酚胺，包括肾上腺素、去甲肾上腺素和多巴胺，是由酪氨酸在一系列酶的催化作用下合成的。儿茶酚胺通过自主调节在生理活动中发挥重要作用，维持人体的动态平衡。儿茶酚胺及其代谢物的异常浓度(特别是高浓度)常提示神经内分泌肿瘤，特别是嗜铬细胞瘤和副神经节瘤的发生。嗜铬细胞瘤和副神经节瘤的显著特点是不规律地释放儿茶酚胺，有时呈爆炸式释放，以及顽固性高血压。正是由于这些性质，嗜铬细胞瘤和副神经节瘤可出现许多严重的并发症，但目前对嗜铬细胞瘤和副神经节瘤的诊断率很低。原因之一是其临床表现具有高度的异质性和多样性，但更重要的原因是缺乏一种筛选和诊断嗜铬细胞瘤和副神经节瘤的超敏方法。目前，医学组织通常通过检测尿液或血浆中的儿茶酚胺来筛查嗜铬细胞瘤和副神经节瘤。然而，儿茶酚胺及其某些代谢物的浓度低、不稳定、极性高、分子结构高度相似，使得儿茶酚胺的准确定量非常困难。本文概述了儿茶酚胺及其代谢物的检测现状，讨论了液相色谱串联质谱法联合检测儿茶酚胺及其代谢物的必要性，阐述了联合检测方法开发与验证的基本步骤及注意事项。
    Catecholamine, including epinephrine, norepinephrine and dopamine, is derived from tyrosine by the catalysis of a series of enzymes. Catecholamines take an important role in physiological activity via autonomic regulation and keep a dynamic balance in human body. The abnormal concentration (particularly the high level) of catecholamines and their metabolites often indicates the occurrence of neuron endocrine neoplasm especially pheochromocytoma and paraganglioma. The prominent features of pheochromocytoma and paraganglioma are releasing Catecholamines irregularly and sometimes explosively as well as refractory hypertension. It is because these nature, pheochromocytoma and paraganglioma can present with lots of serious complications. Unfortunately, the diagnosis rate of pheochromocytoma and paraganglioma is very low. One reason is its high heterogeneity and protean clinical presentation, but the more important reason is lacking a hypersensitive method to screen and diagnose pheochromocytoma and paraganglioma. At present, medical organization usually screens pheochromocytoma and paraganglioma by detecting the Catecholamines in urine or plasma. However, low concentration, instability, high polarity and high similarity in molecular structure of some metabolites make it very difficult for accurate quantification of the Catecholamines. In this paper, the detection status of catecholamine and its metabolites is summarized, the necessity of LC-MS/MS combined detection of catecholamine and its metabolites is discussed, and the basic steps and precautions of the development and verification of the combined detection method are explained. 
  
 
</p></abstract><kwd-group><kwd>液相色谱串联质谱法，儿茶酚胺，嗜铬细胞瘤，甲氧基肾上腺素，甲氧酪胺, Liquid Chromatography Tandem Mass Spectrometry</kwd><kwd> Catecholamines</kwd><kwd> Pheochromocytoma</kwd><kwd> 
Metanephrine</kwd><kwd> Methoxytyramine</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>儿茶酚胺，包括肾上腺素、去甲肾上腺素和多巴胺，是由酪氨酸在一系列酶的催化作用下合成的。儿茶酚胺通过自主调节在生理活动中发挥重要作用，维持人体的动态平衡。儿茶酚胺及其代谢物的异常浓度(特别是高浓度)常提示神经内分泌肿瘤，特别是嗜铬细胞瘤和副神经节瘤的发生。嗜铬细胞瘤和副神经节瘤的显著特点是不规律地释放儿茶酚胺，有时呈爆炸式释放，以及顽固性高血压。正是由于这些性质，嗜铬细胞瘤和副神经节瘤可出现许多严重的并发症，但目前对嗜铬细胞瘤和副神经节瘤的诊断率很低。原因之一是其临床表现具有高度的异质性和多样性，但更重要的原因是缺乏一种筛选和诊断嗜铬细胞瘤和副神经节瘤的超敏方法。目前，医学组织通常通过检测尿液或血浆中的儿茶酚胺来筛查嗜铬细胞瘤和副神经节瘤。然而，儿茶酚胺及其某些代谢物的浓度低、不稳定、极性高、分子结构高度相似，使得儿茶酚胺的准确定量非常困难。本文概述了儿茶酚胺及其代谢物的检测现状，讨论了液相色谱串联质谱法联合检测儿茶酚胺及其代谢物的必要性，阐述了联合检测方法开发与验证的基本步骤及注意事项。</p></sec><sec id="s2"><title>关键词</title><p>液相色谱串联质谱法，儿茶酚胺，嗜铬细胞瘤，甲氧基肾上腺素，甲氧酪胺</p></sec><sec id="s3"><title>Research Progress in the Analysis of Catecholamines and Their Metabolites in Human Body by Liquid Chromatography Tandem Mass Spectrometry</title><p>Yajuan Yan<sup>1</sup>, Meng Huang<sup>2</sup>, Limin Lun<sup>2</sup></p><p><sup>1</sup>Medical College, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/18-1572121x4_hanspub.png" /></p><p>Received: Mar. 12<sup>th</sup>, 2021; accepted: Apr. 9<sup>th</sup>, 2021; published: Apr. 16<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/18-1572121x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Catecholamine, including epinephrine, norepinephrine and dopamine, is derived from tyrosine by the catalysis of a series of enzymes. Catecholamines take an important role in physiological activity via autonomic regulation and keep a dynamic balance in human body. The abnormal concentration (particularly the high level) of catecholamines and their metabolites often indicates the occurrence of neuron endocrine neoplasm especially pheochromocytoma and paraganglioma. The prominent features of pheochromocytoma and paraganglioma are releasing Catecholamines irregularly and sometimes explosively as well as refractory hypertension. It is because these nature, pheochromocytoma and paraganglioma can present with lots of serious complications. Unfortunately, the diagnosis rate of pheochromocytoma and paraganglioma is very low. One reason is its high heterogeneity and protean clinical presentation, but the more important reason is lacking a hypersensitive method to screen and diagnose pheochromocytoma and paraganglioma. At present, medical organization usually screens pheochromocytoma and paraganglioma by detecting the Catecholamines in urine or plasma. However, low concentration, instability, high polarity and high similarity in molecular structure of some metabolites make it very difficult for accurate quantification of the Catecholamines. In this paper, the detection status of catecholamine and its metabolites is summarized, the necessity of LC-MS/MS combined detection of catecholamine and its metabolites is discussed, and the basic steps and precautions of the development and verification of the combined detection method are explained.</p><p>Keywords:Liquid Chromatography Tandem Mass Spectrometry, Catecholamines, Pheochromocytoma, Metanephrine, Methoxytyramine</p><disp-formula id="hanspub.41616-formula12"><graphic xlink:href="//html.hanspub.org/file/18-1572121x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/18-1572121x7_hanspub.png" /> <img src="//html.hanspub.org/file/18-1572121x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 前沿</title><p>儿茶酚胺(catecholamine, CA)，包括肾上腺素(Epinephrine, E)、去甲肾上腺素(Norepinephrine, NE)和多巴胺(Dopamine, DA)，是由酪氨酸在一系列酶的催化作用下产生的。在健康人体内，肾上腺素主要由肾上腺髓质细胞分泌，去甲肾上腺素主要来源于交感神经末梢的溢出，是人体重要的神经递质之一 [<xref ref-type="bibr" rid="hanspub.41616-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41616-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41616-ref3">3</xref>]。多巴胺是大脑中最丰富的儿茶酚胺类神经递质，缺乏多巴胺是帕金森病的重要特征。鲜为人知的是肾上腺和肾上腺外嗜铬细胞也能分泌多巴胺 [<xref ref-type="bibr" rid="hanspub.41616-ref4">4</xref>]。甲氧基肾上腺素(metanephrine, MN)，甲氧基去甲肾上腺素(normetanephrine, NMN)，3-甲氧酪胺(3-methoxytyramine, 3-MT)是肾上腺素、去甲肾上腺素及多巴胺在儿茶酚-O-甲基转移酶催化作用下的中间代谢产物。高香草酸(homovanillic acid, HVA)和香草扁桃酸(Vanillylmandelic Acid, VMA)是肾上腺素、去甲肾上腺素和多巴胺的最终产物。儿茶酚胺通过自主调节以保持人体的动态平衡在生理活动中发挥了重要的作用。儿茶酚胺及其代谢物的异常浓度(尤其是高水平)常提示神经内分泌肿瘤，尤其是嗜铬细胞瘤和副神经节瘤(pheochromocytoma and paraganglioma, PPGL)的发生 [<xref ref-type="bibr" rid="hanspub.41616-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41616-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.41616-ref7">7</xref>]。</p><p>嗜铬细胞瘤和副神经节瘤是分别从肾上腺髓质细胞和肾上腺外嗜铬细胞中发生的神经内分泌肿瘤 [<xref ref-type="bibr" rid="hanspub.41616-ref8">8</xref>]，发病率低于十万分之一 [<xref ref-type="bibr" rid="hanspub.41616-ref9">9</xref>]。PPGL的显著特点是不规律地释放儿茶酚胺，有时呈爆发性释放，同时伴有难治性高血压 [<xref ref-type="bibr" rid="hanspub.41616-ref10">10</xref>]。由于这些性质，PPGL可以出现许多严重的并发症，如果诊断和治疗晚可能造成生命威胁。不幸的是，PPGL的诊断率很低。原因之一是其临床表现具有高度的异质性和多样性 [<xref ref-type="bibr" rid="hanspub.41616-ref11">11</xref>]，但更重要的原因是缺乏一种超敏的筛选和鉴别PPGL的方法。目前，医疗机构通常通过尿液或血浆中的儿茶酚胺及其代谢产物来筛查PPGL。然而，儿茶酚胺及其某些代谢产物的浓度低、不稳定、极性高、分子结构相似等特点使得儿茶酚胺及其某些代谢产物的准确测定非常困难 [<xref ref-type="bibr" rid="hanspub.41616-ref12">12</xref>]。</p><p>目前用于儿茶酚胺及其代谢产物检测的方法有酶免疫测定(enzyme immunoassay, EIA)，高效液相色谱电化学分析(high performance liquid chromatography with electrochemical detection, HPLC-ECD)，高效液相色谱串联质谱分析(high performance liquid chromatography-tandem mass spectrometry, HPLC-MS/MS)等。其中最简单、应用最广泛的方法是酶免疫测定法 [<xref ref-type="bibr" rid="hanspub.41616-ref13">13</xref>]，但由于其灵敏度和选择性较差，且样品制备时间较长，使得酶免疫测定在这两种方法中处于劣势。此外，酶免疫测定法不能测量3-甲氧酪胺，而3-甲氧酪胺是预测PPGL预后的重要指标。对于高效液相色谱电化学分析，由于其相对较高的准确度和精密度，最初被作为检测儿茶酚胺及其代谢产物的主要方法，但因为它采样缓慢、低采样率、样品制备复杂以及不可避免的分析干扰等缺点，现在已经被酶免疫测定和LC-MS/MS所取代。与酶免疫测定和HPLC-ECD相比，LC-MS/MS具有简单、快速、灵敏和选择性的优点，并且可以一次进样同时测定多种儿茶酚胺及其代谢产物，因此被越来越多的实验室和研究人员认可并应用于临床检验以及PPGL的辅助诊断 [<xref ref-type="bibr" rid="hanspub.41616-ref14">14</xref>]。</p></sec><sec id="s6"><title>2. 儿茶酚胺及其代谢产物在人体内的代谢通路</title><p>虽然在血液中儿茶酚胺及其代谢产物的浓度很低，但是儿茶酚胺及其代谢产物由体内的一系列酶持续代谢，不断产生和消耗，维持动态平衡。循环中的儿茶酚胺过多通常会导致心脏和血管的高血压和靶器官损害(Target Organ Damage, TOD)，而过少则可能导致低血压。另一方面，血浆中儿茶酚胺及其代谢物的异常变化常提示相关疾病，如神经母细胞瘤、甲状腺功能亢进等。此外，影响循环中儿茶酚胺水平的生理因素也很多，例如年龄、性别、昼夜节律、饮食、药物、情绪、体位等 [<xref ref-type="bibr" rid="hanspub.41616-ref15">15</xref>]。</p><p>儿茶酚胺的代谢非常复杂，如前所述，去甲肾上腺素主要由交感神经产生，交感细胞表达单胺氧化酶(monoamine oxidase, MAO)而不表达儿茶酚-O-甲基转移酶(catechol-o-methyltransferase, COMT)，所以去甲肾上腺素被MAO氧化脱氨，在交感神经中形成3,4-二羟基苯乙二醇(3,4-dihydroxyphenylglycol, DHPG) [<xref ref-type="bibr" rid="hanspub.41616-ref16">16</xref>]。DHPG进入循环，在肝脏中代谢为3-甲基-4-羟基苯乙二醇(3-methoxy-4-hydroxyphenylglycol, MHPG)。DHPG和MHPG最终转化为香草扁桃酸。MAO和COMT均存在于肾上腺髓质细胞中。因此，肾上腺素、去甲肾上腺素在肝脏中可以被分解成甲氧基肾上腺素、甲氧基去甲肾上腺素，最终代谢成香草扁桃酸。在胃肠道中，有一种特殊类型的硫转移酶，称为SULT1A3，它可以将游离的儿茶酚胺及其代谢产物转化为硫酸盐结合的代谢产物。在这些硫酸盐结合物中，几乎所有的结合甲氧基肾上腺素都来源于肾上腺髓质分泌的游离甲氧基肾上腺素，而大量的结合甲氧基去甲肾上腺素则来源于胃肠道产生的去甲肾上腺素。因此，结合甲氧基去甲肾上腺素的血浆浓度主要反映去甲肾上腺素的胃肠道代谢，而结合甲氧基肾上腺素的血浆浓度则反映肾上腺素的肾上腺髓质代谢。对于多巴胺，循环中的多巴胺大部分来自于胃肠道对食物的吸收和代谢，99%的多巴胺处于结合状态。由于尿中多巴胺主要由肾脏提取和循环左旋多巴(Levodopa，L-DOPA)脱羧作用形成，因此尿中多巴胺浓度较高并且不能用于诊断嗜铬细胞瘤 [<xref ref-type="bibr" rid="hanspub.41616-ref17">17</xref>]。</p></sec><sec id="s7"><title>3. 儿茶酚胺及其代谢产物的检测</title><sec id="s7_1"><title>3.1. 肾上腺素、去甲肾上腺素、多巴胺</title><p>儿茶酚胺作为第一个被发现的与PPGL有关的生物标志物，最初被广泛应用于PPGL的诊断。目前儿茶酚胺检测方法有很多，以前常用的主要有液相色谱电化学、液相色谱荧光检测、毛细管电泳、放射酶学等，其中，LC-MS/MS因其能够同时在灵敏度、特异性以及检测速度等方面均能达到临床检验要求而越来越多地被研究并应用于临床检测。</p><p>另一方面，儿茶酚胺类化合物的半衰期短、挥发性大、浓度低、稳定性差，对准确测定一直是一个很大的挑战 [<xref ref-type="bibr" rid="hanspub.41616-ref18">18</xref>]。此外，儿茶酚胺的测量对某些特殊类型的PPGL诊断不敏感，比如不分泌或间断性分泌儿茶酚胺的PPGL。因此，随着对儿茶酚胺代谢认识的提高，目前儿茶酚胺测定逐渐被其代谢物如甲氧基肾上腺素、甲氧基去甲肾上腺素和甲氧酪胺等所取代。但对于那些仅分泌多巴胺的罕见PPGL的检测，儿茶酚胺的检测仍是不可替代 [<xref ref-type="bibr" rid="hanspub.41616-ref19">19</xref>]。目前，儿茶酚胺检测所面临的问题是循环中儿茶酚胺浓度低、易波动，不稳定，采集后不易保存。为了解决这些问题我们可以采取一些措施，例如，采取LC-MS/MS等准确的检测方法，坚持仰卧位静息后采样和采样前严格的饮食要求，样品避光保存于−80℃冰箱等 [<xref ref-type="bibr" rid="hanspub.41616-ref20">20</xref>]。</p></sec><sec id="s7_2"><title>3.2. 高香草酸、香草扁桃酸</title><p>高香草酸和香草扁桃酸作为儿茶酚胺在尿液中排泄的最丰富的终产物，由于其稳定性、排泄量大、易检测等特点在PPGL分析中也得到了广泛的应用。大多数PPGL产生相对少量的多巴胺，但某些特殊类型的肿瘤，尤其是孤立的副神经节瘤主要产生多巴胺，很少分泌肾上腺素和去甲肾上腺素。高香草酸和香草扁桃酸是神经母细胞瘤生化诊断的主要代谢物，在神经母细胞瘤(neuroblastoma, NBL)的诊断中，香草扁桃酸与高香草酸比值小于0.5与晚期疾病和不良预后相关。目前测定香草扁桃酸与高香草酸的方法很多，其中，液相色谱串联质谱法因其高灵敏度、高选择性、同时多项目分析等优点有利于儿茶酚胺及其代谢物的综合分析而被越来越多的关注及研究 [<xref ref-type="bibr" rid="hanspub.41616-ref21">21</xref>]。</p></sec><sec id="s7_3"><title>3.3. 甲氧基肾上腺素、甲氧基去甲肾上腺素、甲氧酪胺</title><p>随着对儿茶酚胺代谢认识的不断深入，肾上腺素和去甲肾上腺素的中间代谢产物甲氧基肾上腺素、甲氧基去甲肾上腺素，即甲氧基肾上腺素类物质(MNs)被广泛认为是诊断PPGL最敏感的儿茶酚胺代谢物。人们普遍认为游离MNs优于结合MNs，血浆代谢物检测PPGL比尿液检测PPGL具有更高的灵敏度和选择性 [<xref ref-type="bibr" rid="hanspub.41616-ref22">22</xref>]。然而，被人们所忽略的是，在循环中游离MNs和儿茶酚胺代谢及清除是一样快的 [<xref ref-type="bibr" rid="hanspub.41616-ref23">23</xref>]，并且在MNs的检测中，假阳性现象较多。只有坚持严格的分析前采样预防措施，适当的参考区间和先进的测量方法，才能保证准确的检测结果。取仰卧位、空腹、24 h内不吃含儿茶酚胺类(尤其是多巴胺)的食物或药物采样是准确定量分析的关键。另外，如果不能做到禁食取仰卧位，尿液检查可能是首选的检查方法。随着年龄的增长，循环甲氧基去甲肾上腺素的浓度显著增加，而男性的甲氧基肾上腺素和甲氧酪胺水平高于女性，因此，建立甲氧基肾上腺素的性别参考区间和甲氧基去甲肾上腺素的年龄参区间非常重要 [<xref ref-type="bibr" rid="hanspub.41616-ref24">24</xref>]。同时具备高通量、高灵敏度、高选择性和一次进样多重分析等优势，高效液相色谱–质谱联用技术(HPLC-MS/MS)被认为是检测循环中MNs的最佳方法。</p><p>3-甲氧酪胺作为多巴胺的3-O-甲基化代谢产物，在神经母细胞瘤(Neuroblastoma, NBL)和PPGL的分析中起着重要作用。3-甲氧酪胺与神经母细胞瘤检测的几乎所有生物学和临床参数有关，并与晚期、高龄、骨狭窄等多种预后因素有关 [<xref ref-type="bibr" rid="hanspub.41616-ref25">25</xref>]。3-甲氧酪胺是一种良好的独立预后生物标志物，提示着神经母细胞瘤患者的高风险和不良结局 [<xref ref-type="bibr" rid="hanspub.41616-ref26">26</xref>]。另一方面，3-甲氧酪胺也是诊断特殊类型PPGL的一个重要的标志物。在大多数PPGL中均可发现MNs的增加，但也有部分肿瘤仅产生多巴胺，这与琥珀酸脱氢酶B (SDHB)基因的潜在突变或转移瘤有关，转移瘤患者血浆多巴胺水平明显高于非转移性肿瘤患者，检测3-甲氧酪胺有助于诊断这两类肿瘤。值得注意的是，与血浆相比，尿液中游离或去结合的3-甲氧酪胺水平对于诊断产生多巴胺的PPGL的诊断作用有限 [<xref ref-type="bibr" rid="hanspub.41616-ref27">27</xref>]。与酶免疫分析法相比，HPLC-MS/MS可以准确地检测3-甲氧酪胺，因此在儿茶酚胺代谢物分析中越来越受欢迎。</p></sec></sec><sec id="s8"><title>4. 儿茶酚胺及其代谢产联合检测的开发与验证</title><p>随着科学技术的进步，色谱仪和质谱仪也不断地改进与发展，目前已经研制出先进的能同时扫描正离子和负离子并同时检测数百对离子的质谱仪 [<xref ref-type="bibr" rid="hanspub.41616-ref28">28</xref>]。八种儿茶酚胺及其代谢物联合检测可以提高神经母细胞瘤和PPGL诊断的敏感性和选择性。Dubois认为联合检测可以分析仅产生多巴胺的PPGLs，即多巴胺分泌型嗜铬细胞瘤 [<xref ref-type="bibr" rid="hanspub.41616-ref29">29</xref>]。一些研究表明联合检测可以确保神经母细胞瘤诊断的最佳灵敏度，特别是对于某些难以诊断的类型，例如间碘苄胍非亲和肿瘤患者和无高香草酸和香草扁桃酸升高的患者 [<xref ref-type="bibr" rid="hanspub.41616-ref30">30</xref>]。而且对于PPGL，联合检测在鉴别不同突变类型的也起着重要的作用，不同突变类型在儿茶酚胺的相对含量和总量上存在差异。基因突变是肿瘤发生的关键，导致不同的代谢途径，从而产生不同的儿茶酚胺生化表型 [<xref ref-type="bibr" rid="hanspub.41616-ref31">31</xref>]。儿茶酚胺及其代谢产物的联合生化检测可以为选择检测基因类型提供重要的指导。另一方面，儿茶酚胺的生化谱也反映了神经母细胞瘤中不同类型的突变，不同的生化结果反映了神经母细胞瘤的不同亚群 [<xref ref-type="bibr" rid="hanspub.41616-ref32">32</xref>]。此外，联合检测可用于假性嗜铬细胞瘤的辅助诊断，假性嗜铬细胞瘤与嗜铬细胞瘤具有相同的症状和体征，但在影像学和生物化学上无异常，联合检测为其提供了一种有效的鉴别方法 [<xref ref-type="bibr" rid="hanspub.41616-ref33">33</xref>]。</p><p>HPLC-MS/MS已广泛应用于临床生化检测，是未来临床检验的发展趋势，然而由于儿茶酚胺及其代谢产物浓度低、品种多、结构相似，对一次进样同时检测多种儿茶酚胺及其代谢产物的准确性提出了很大的挑战。由于高灵敏度、高选择性和同时多重分析等特点，LC-MS/MS可以快速、准确地对这些代谢物进行定量检测。但需要注意的是，在方法开发后，每种定量分析物的LC-MS/MS检测应在临床使用前验证方法并确保每个分析物的性能分析满足要求。</p><p>LC-MS/MS方法的开发主要包括：1) 样品处理：与其他检测方法相比，LC-MS/MS样品制备方法相对很简单。提取方法主要包括：固相萃取(solid-phase extration, SPE)、蛋白质沉淀、液–液萃取(liqui-liquid extraction, LLE)等。适当的提取方法可以提高样品纯化效率，减少基质干扰。固相萃取(SPE)是最流行的样品制备技术，它可以最大限度地减少内源性血浆成分(如磷脂、盐和蛋白质，可能导致离子抑制)对基质的影响。2) 液相色谱：液相条件的优化主要包括色谱柱的选择、流动相的优化和梯度的优化。与其它色谱体系相比，液相色谱具有广泛的固定相、柱径和流动相添加物组合，可以用来寻找最佳的色谱条件 [<xref ref-type="bibr" rid="hanspub.41616-ref34">34</xref>]。3) 质谱：质谱优化包括电离模式、离子对、电离参数和离子源的选择。目前，电喷雾电离(electrospray ionization, ESI)是代谢组学研究中最常用的方法。儿茶酚胺及其代谢产物均为极性化合物，以正离子(胺)或负离子(酸)的形式存在于溶液中，因此ESI是最常采用的电离模式。4) 干扰及其他影响因素：与其他方法相比，LC-MS/MS法分析的干扰相对较小。液相色谱的应用可以避免许多干扰，例如，3-O-甲基多巴与甲氧酪胺在质荷比上相似，质谱不能将其分离。然而，应用液相色谱法可以分离这两种物质物质。尽管如此，影响实验结果的因素还包括受试者的采血姿势、受试者的饮食、某些药物的应用等，这些都可能导致假阳性。此外，性别对血浆甲氧基肾上腺素有显著影响，男性血浆甲氧基肾上腺素水平高于女性 [<xref ref-type="bibr" rid="hanspub.41616-ref24">24</xref>]。血浆甲氧基酪胺、甲氧基去甲肾上腺素和3-O-甲基多巴随年龄的变化对婴幼儿的检测结果有很大影响。有证据表明，从新生儿到3岁左右，血浆甲氧基酪胺、甲氧基去甲肾上腺素和3-O-甲基多巴浓度急剧下降，因此建立合适的参考区间是非常重要的 [<xref ref-type="bibr" rid="hanspub.41616-ref35">35</xref>]。</p><p>联合检测需要同时检测多种儿茶酚胺及其代谢物，因此在联合检测中需要选择最优参数，以保证每一种物质都能被准确检测到。方法建立后，应严格进行方法验证，方可用于临床。方法验证的主要内容包括：检测限、定量检测下限、不精确度、准确性、干扰、稀释一致性、稳定性以及方法论的互动认证。方法验证需要综合评估各个方面的细微影响，如果该方法的性能发生显著变化，则需要再次对该方法进行改进，重新进行方法验证，直到该方法的性能能够满足临床试验的要求。</p></sec><sec id="s9"><title>5. 小结</title><p>PPGL的误诊将会带来很多问题，甚至导致致命的后果。由于儿茶酚胺及其代谢物种类众多，结构相似，含量低，LC-MS/MS的高通量、敏感性和特异性使其成为儿茶酚胺及其代谢物准确检测的首选方法。由于LC-MS/MS一次进样可检测多种物质，更直观地显示各种儿茶酚胺及其代谢物的变化，有利于临床诊断、治疗和预后检测。目前，LC-MS/MS检测儿茶酚胺及其代谢物的方法在世界各地的实验室得到了越来越多的开发和应用。需要注意的是，质谱仪的成本高，操作复杂，每个临床实验室在使用前都需要建立并验证自己的检测方法，这对操作人员来说是一个很大的挑战。本文概述了儿茶酚胺及其代谢物的检测现状，讨论了LC-MS/MS联合检测儿茶酚胺及其代谢物的必要性，阐述了联合检测方法开发与验证的基本步骤及注意事项。与其它检测方法相比，LC-MS/MS方法表现出越来越多的优势。随着质谱仪的不断改进，灵敏度和自动化程度的不断提高，LC-MS/MS在临床检测儿茶酚胺及其代谢物方面的应用将会越来越广泛。</p></sec><sec id="s10"><title>文章引用</title><p>闫亚娟,黄 猛,伦立民. 液相色谱串联质谱法分析人体内儿茶酚胺及其代谢产物的研究进展Research Progress in the Analysis of Catecholamines and Their Metabolites in Human Body by Liquid Chromatography Tandem Mass Spectrometry[J]. 临床医学进展, 2021, 11(04): 1571-1578. https://doi.org/10.12677/ACM.2021.114225</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41616-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhofer, G., Huynh, T., Hiroi, M., et al. (2001) Understanding Catecholamine Metabolism as a Guide to the Biochemical Diagnosis of Pheochromocytoma. Reviews in Endocrine and Metabolic Disorders, 2, 297-311.  
&lt;br&gt;https://doi.org/10.1023/A:1011572617314</mixed-citation></ref><ref id="hanspub.41616-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhofer, G., Rundquist, B., Aneman, A., et al. (1995) Regional Release and Removal of Catecholamines and Extraneuronal Metabolism to Metanephrines. The Journal of Clinical Endocrinology and Metabolism, 80, 3009-3017.  
&lt;br&gt;https://doi.org/10.1210/jcem.80.10.7559889</mixed-citation></ref><ref id="hanspub.41616-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Niwa, M., Matsumoto, Y., Mouri, A., et al. (2011) Vulnerability in Early Life to Changes in the Rearing Environment Plays a Crucial Role in the Aetiopathology of Psychiatric Disorders. The International Journal of Neuropsychopharmacology, 14, 459-477. &lt;br&gt;https://doi.org/10.1017/S1461145710001239</mixed-citation></ref><ref id="hanspub.41616-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhofer, G., Kopin, I.J. and Goldstein, D.S. (2004) Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine. Pharmacological Reviews, 56, 331-349. &lt;br&gt;https://doi.org/10.1124/pr.56.3.1</mixed-citation></ref><ref id="hanspub.41616-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Gu, Y.W., Poste, J., Kunal, M., et al. (2017) Cardiovascular Manifestations of Pheochromocytoma. Cardiology in Review, 25, 215-222. &lt;br&gt;https://doi.org/10.1097/CRD.0000000000000141</mixed-citation></ref><ref id="hanspub.41616-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Prejbisz, A., Lenders, J.W.M., Eisenhofer, G., et al. (2013) Mortality Associated with Phaeochromocytoma. Hormone and Metabolic Research, 45, 154. &lt;br&gt;https://doi.org/10.1055/s-0032-1331217</mixed-citation></ref><ref id="hanspub.41616-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Stolk, R.F., Bakx, C., Mulder, J., et al. (2013) Is the Excess Cardiovascular Morbidity in Pheochromocytoma Related to Blood Pressure or to Catecholamines? The Journal of Clinical Endocrinology &amp; Metabolism, 98, 1100-1106.  
&lt;br&gt;https://doi.org/10.1210/jc.2012-3669</mixed-citation></ref><ref id="hanspub.41616-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lenders, J.W., Eisenhofer, G., Mannelli, M., et al. (2005) Phaeochromocytoma. The Lancet, 366, 665-675.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(05)67139-5</mixed-citation></ref><ref id="hanspub.41616-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Berends, A.M.A., Buitenwerf, E., de Krijger, R.R., et al. (2018) Incidence of Pheochromocytoma and Sympathetic Paraganglioma in the Netherlands: A Nationwide Study and Systematic Review. European Journal of Internal Medicine, 51, 68-73. &lt;br&gt;https://doi.org/10.1016/j.ejim.2018.01.015</mixed-citation></ref><ref id="hanspub.41616-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zuber, S.M., Kantorovich, V. and Pacak, K. (2011) Hypertension in Pheochromocytoma: Characteristics and Treatment. Endocrinology and Metabolism Clinics of North America, 40, 295-311. &lt;br&gt;https://doi.org/10.1016/j.ecl.2011.02.002</mixed-citation></ref><ref id="hanspub.41616-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Manger, W.M. (2009) The Protean Manifestations of Pheochromocytoma. Hormone and Metabolic Research, 41, 658.  
&lt;br&gt;https://doi.org/10.1055/s-0028-1128139</mixed-citation></ref><ref id="hanspub.41616-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Li, X.S., Li, S. and Kellermann, G. (2016) Pre-Analytical and Analytical Validations and Clinical Applications of a Miniaturized, Simple and Cost-Effective Solid Phase Extraction Combined with LC-MS/MS for the Simultaneous Determination of Catecholamines and Metanephrines in Spot Urine Samples. Talanta, 159, 238-247.  
&lt;br&gt;https://doi.org/10.1016/j.talanta.2016.06.032</mixed-citation></ref><ref id="hanspub.41616-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Pussard, E., Chaouch, A. and Said, T. (2014) Radioimmunoassay of Free Plasma Metanephrines for the Diagnosis of Catecholamine-Producing Tumors. Clinical Chemistry and Laboratory Medicine, 52, 437-444.  
&lt;br&gt;https://doi.org/10.1515/cclm-2013-0406</mixed-citation></ref><ref id="hanspub.41616-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhofer, G., Peitzsch, M. and Mcwhinney, B.C. (2016) Impact of LC-MS/MS on the Laboratory Diagnosis of Catecholamine-Producing Tumors. TrAC Trends in Analytical Chemistry, 84, 106-116.  
&lt;br&gt;https://doi.org/10.1016/j.trac.2016.01.027</mixed-citation></ref><ref id="hanspub.41616-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Davies, S.L. and Davison, A.S. (2019) Liquid Chromatography Tandem Mass Spectrometry for Plasma Metadrenalines. Clinica Chimica Acta, 495, 512-521. &lt;br&gt;https://doi.org/10.1016/j.cca.2019.05.024</mixed-citation></ref><ref id="hanspub.41616-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhofer, G. and Peitzsch, M. (2014) Laboratory Evaluation of Pheochromocytoma and Paraganglioma. Clinical Chemistry, 60, 1486-1499. &lt;br&gt;https://doi.org/10.1373/clinchem.2014.224832</mixed-citation></ref><ref id="hanspub.41616-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhofer, G., Lenders, J.W.M., Siegert, G., et al. (2012) Plasma Methoxytyramine: A Novel Biomarker of Metastatic Pheochromocytoma and Paraganglioma in Relation to Established Risk Factors of Tumour Size, Location and SDHB Mutation Status. European Journal of Cancer, 48, 1739-1749. &lt;br&gt;https://doi.org/10.1016/j.ejca.2011.07.016</mixed-citation></ref><ref id="hanspub.41616-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Willemsen, J.J., Ross, H.A., Lenders, J.W., et al. (2007) Stability of Urinary Fractionated Metanephrines and Catecholamines during Collection, Shipment, and Storage of Samples. Clinical Chemistry, 53, 268-272.  
&lt;br&gt;https://doi.org/10.1373/clinchem.2006.075218</mixed-citation></ref><ref id="hanspub.41616-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chen, H., Sippel, R.S., O’dorisio, M.S., et al. (2010) The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas, 39, 775-783.  
&lt;br&gt;https://doi.org/10.1097/MPA.0b013e3181ebb4f0</mixed-citation></ref><ref id="hanspub.41616-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Berends, A., Eisenhofer, G., Fishbein, L., et al. (2019) Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma. Cancers (Basel), 11, 1121. &lt;br&gt;https://doi.org/10.3390/cancers11081121</mixed-citation></ref><ref id="hanspub.41616-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Grouzmann, E., Centeno, C. and Eugster, P.J. (2018) Quantification of Vanillylmandelic Acid, Homovanillic Acid and 5-Hydroxyindoleacetic Acid in Urine Using a Dilute-and-Shoot and Ultra-High Pressure Liquid Chromatography Tandem Mass Spectrometry Method. Clinical Chemistry and Laboratory Medicine (CCLM), 56, 1533-1541.  
&lt;br&gt;https://doi.org/10.1515/cclm-2017-1120</mixed-citation></ref><ref id="hanspub.41616-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhofer, G., Prejbisz, A., Peitzsch, M., et al. (2018) Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clinical Chemistry, 64, 1646-1656. &lt;br&gt;https://doi.org/10.1373/clinchem.2018.291369</mixed-citation></ref><ref id="hanspub.41616-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhofer, G. and Lenders, J.W.M. (2018) Biochemical Diagnosis of Pheochromocytoma, a Rediscovered Catecholamine-Metabolizing Tumor. Clinical Chemistry, 64, 1780-1781. &lt;br&gt;https://doi.org/10.1373/clinchem.2018.290791</mixed-citation></ref><ref id="hanspub.41616-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhofer, G., Peitzsch, M., Kaden, D., et al. (2019) Reference Intervals for LC-MS/MS Measurements of Plasma Free, Urinary Free and Urinary Acid-Hydrolyzed Deconjugated Normetanephrine, Metanephrine and Methoxytyramine. Clinica Chimica Acta, 490, 46-54. &lt;br&gt;https://doi.org/10.1016/j.cca.2018.12.019</mixed-citation></ref><ref id="hanspub.41616-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Verly, I.R., van Kuilenburg, A.B., Abeling, N.G.G.M., et al. (2017) Catecholamines Profiles at Diagnosis: Increased Diagnostic Sensitivity and Correlation with Biological and Clinical Features in Neuroblastoma Patients. European Journal of Cancer, 72, 235-243. &lt;br&gt;https://doi.org/10.1016/j.ejca.2016.12.002</mixed-citation></ref><ref id="hanspub.41616-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Verly, I.R.N., van Kuilenburg, A.B.P., Abeling, N.G.G.M., et al. (2018) 3-Methoxytyramine: An Independent Prognostic Biomarker That Associates with High-Risk Disease and Poor Clinical Outcome in Neuroblastoma Patients. European Journal of Cancer, 90, 102-110. &lt;br&gt;https://doi.org/10.1016/j.ejca.2017.11.025</mixed-citation></ref><ref id="hanspub.41616-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Patin, F., Crinière, L., Francia, T., et al. (2016) Low Specificity of Urinary 3-Methoxytyramine in Screening of Dopamine-Secreting Pheochromocytomas and Paragangliomas. Clinical Biochemistry, 49, 1205-1208.  
&lt;br&gt;https://doi.org/10.1016/j.clinbiochem.2016.05.008</mixed-citation></ref><ref id="hanspub.41616-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Zhou, L., Lei, H., et al. (2017) Simultaneous Quantification of Amino Metabolites in Multiple Metabolic Pathways Using Ultra-High Performance Liquid Chromatography with Tandem-Mass Spectrometry. Scientific Reports, 7, 1416-1423. &lt;br&gt;https://doi.org/10.1038/s41598-017-01435-7</mixed-citation></ref><ref id="hanspub.41616-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Yu, S., Yin, Y., Li, Q., et al. (2019) Validation of an Improved Liquid Chromatography Tandem Mass Spectrometry Method for Rapid and Simultaneous Analysis of Plasma Catecholamine and Their Metabolites. Journal of Chromatography B, 1129, Article ID: 121805. &lt;br&gt;https://doi.org/10.1016/j.jchromb.2019.121805</mixed-citation></ref><ref id="hanspub.41616-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Verly, I.R., Van Kuilenburg, A.B., Abeling, N.G., et al. (2017) Catecholamines Profiles at Diagnosis: Increased Diagnostic Sensitivity and Correlation with Biological and Clinical Features in Neuroblastoma Patients. European Journal of Cancer, 72, 235-243. &lt;br&gt;https://doi.org/10.1016/j.ejca.2016.12.002</mixed-citation></ref><ref id="hanspub.41616-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Rao, J.U., Engelke, U.F.H., Rodenburg, R.J.T., et al. (2013) Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 19, 3787-3795. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-12-3922</mixed-citation></ref><ref id="hanspub.41616-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Verly, I.R.N., Leen, R., Meinsma, J.R., et al. (2019) Catecholamine Excretion Profiles Identify Clinical Subgroups of Neuroblastoma Patients. European Journal of Cancer, 111, 21-29. &lt;br&gt;https://doi.org/10.1016/j.ejca.2019.01.014</mixed-citation></ref><ref id="hanspub.41616-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Mamilla, D., Gonzales, M.K., Esler, M.D., et al. (2019) Pseudopheochromocytoma. Endocrinology and Metabolism Clinics of North America, 48, 751-764. &lt;br&gt;https://doi.org/10.1016/j.ecl.2019.08.004</mixed-citation></ref><ref id="hanspub.41616-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Rodríguez-Morató, J., Pozo, Ó.J. and Marcos, J. (2018) Targeting Human Urinary Metabolome by LC-MS/MS: A Review. Bioanalysis, 10, 489-516. &lt;br&gt;https://doi.org/10.4155/bio-2017-0285</mixed-citation></ref><ref id="hanspub.41616-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Peitzsch, M., Mangelis, A., Eisenhofer, G., et al. (2019) Age-Specific Pediatric Reference Intervals for Plasma Free Normetanephrine, Metanephrine, 3-Methoxytyramine and 3-O-Methyldopa: Particular Importance for Early Infancy. Clinica Chimica Acta, 494, 100-105. &lt;br&gt;https://doi.org/10.1016/j.cca.2019.03.1620</mixed-citation></ref></ref-list></back></article>